AstraZeneca PLC (AZN) annual results, year to 31 December 2016: revenue USD 23,002 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2016 it reported revenue of USD 23,002 million, down 6.9% on the year before. Its profit attributable to shareholders was USD 3,499 million, up 23.9%, and diluted earnings per share USD 2.76.
The year to 31 December 2016, against the year before
| Year to | Dec 2015 | Dec 2016 |
|---|---|---|
| Revenue | 24,708 | 23,002 |
| Cost of sales | 4,646 | 4,126 |
| Gross profit | 20,062 | 18,876 |
| Research and development | 5,997 | 5,890 |
| Selling, general and administrative | 11,112 | 9,413 |
| Operating profit | 4,114 | 4,902 |
| Finance costs | 1,075 | 1,384 |
| Profit before tax | 3,069 | 3,552 |
| Income tax | 243 | 146 |
| Profit for the year | 2,826 | 3,406 |
| Profit attributable to shareholders | 2,825 | 3,499 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2015 | Dec 2016 |
|---|---|---|
| Cash from operations | 3,324 | 4,145 |
| Purchase of property, plant and equipment | 1,328 | 1,446 |
| Free cash flow | 1,996 | 2,699 |
| Dividends paid | 3,486 | 3,561 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2015 | Dec 2016 |
|---|---|---|
| Total assets | 60,056 | 62,526 |
| Equity attributable to shareholders | 18,490 | 14,854 |
| Cash and cash equivalents | 6,240 | 5,018 |
| Trade and other receivables | 6,622 | 4,573 |
| Inventories | 2,143 | 2,334 |
| Goodwill | 11,800 | 11,658 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2015 | Dec 2016 |
|---|---|---|
| Gross margin | 81.2% | 82.1% |
| Operating margin | 16.7% | 21.3% |
| Net margin | 11.4% | 15.2% |
| Free cash flow margin | 8.1% | 11.7% |
| Return on year-end equity | 15.3% | 23.6% |
| Effective tax rate | 7.9% | 4.1% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016, this page
- Year to 31 December 2015
Source
20-F for the year to 31 December 2016, filed 5 March 2019, accession 0001104659-19-012881: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.